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Aim: The role of gastrectomy in glycemic control has been established in the current era of bariatric 
surgery for obesity. Gastrectomy in obese patients is associated with increased levels of high-density 
lipoprotein cholesterol (HDL-C). However, limited data on the effects of gastrectomy in nonobese 
patients are available. We herein investigated the long-term plasma lipid changes in nonobese 
patients who had undergone gastrectomy.
Methods: Patients were enrolled as part of routine healthcare examinations from 1984 to 2003. Pre-
operative and postoperative data from patients who had undergone curative gastrectomy were ana-
lyzed for up to 10 years postoperatively. Three age- and sex-matched controls were assigned to each 
case.
Results: Sixty-four nonobese patients without diabetes mellitus or a history of having taken lipid-
lowering drugs who underwent curative gastrectomy during the study period were enrolled (60 sub-
total gastrectomies, four total gastrectomies). The median follow-up period was 7.6 years. The mean 
body mass index was 9.6% lower one year after gastrectomy (p＜0.01), then plateaued with a slight 
recovery. Intriguingly, the preoperative HDL-C level was 21% higher one year after gastrectomy (p＜
0.01), increased by another 30% six years after gastrectomy and remained at this level for the rest of 
the follow-up period. No significant changes in the HDL-C level were observed in the controls. The 
degree of HDL-C elevation was consistently significant, irrespective of the baseline triglyceride level, 
HDL-C level or body weight.
Conclusions: Gastrectomy in nonobese patients was associated with consistent and distinct long-
term HDL-C elevations and body mass index reductions.
J Atheroscler Thromb, 2015; 22: 235-246.
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Introduction
There is great interest in raising the high-density 
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lipoprotein cholesterol (HDL-C) level, because a low 
HDL-C level is a strong predictor of morbidity and 
mortality among patients with coronary heart dis-
ease1). In contrast to the low-density lipoprotein cho-
lesterol (LDL-C) level, the level of which can be dra-
matically reduced with statins, only a modest HDL-C 
elevation can be achieved with statins or fibrates. 
Therefore, new techniques for elevating the HDL-C 
level have been eagerly anticipated. Low HDL-C lev-
els predict the future occurrence of type 2 diabetes 
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school employees in adjacent areas and has examined 
approximately 6,300 patients every year since 1964. 
At the checkups, patients undergo comprehensive 
evaluations including a complete medical history, his-
tory of cigarette smoking and alcohol intake, physical 
examination, anthropometric measurements (height 
and body weight), and laboratory testing, including 
most routine blood analyses. These annual health 
checkups are mandatory for public school teachers in 
Japan; thus, this heath checkup record system provides 
an unparalleled resource for long-term follow-up stud-
ies. This study was approved by the institutional 
review board at Hokuriku Central Hospital, and 
signed informed consent was obtained from all partic-
ipants. 
Study Population 
We identified 64 patients (cases) who underwent 
gastrectomy during the study period, and analyzed all 
of these cases’ preoperative and postoperative data. 
Three age- and sex-matched controls were randomly 
selected in the same year for each of the 64 cases (64×
3=192 patients). The median follow-up duration was 
7.6 years (range, 1-10 years), and the number of 
observations decreased over time, as shown in Fig.1A. 
Patients (cases) who had undergone gastrectomy thus 
appear to have been prescribed acid-reducing drugs 
more frequently than the controls. Only cimetidine, a 
histamine H2-receptor antagonist, reportedly increases 
the HDL-C levels8); however, no patients were pre-
scribed cimetidine in this study.
Data Collection and Study Variables
Using the “year of gastrectomy” as a reference 
point, the following data were collected for two years 
before gastrectomy (preoperative data) and up to 10 
years after gastrectomy (postoperative data) for each 
individual case: age, sex, height, weight, BMI, type of 
gastrectomy (partial or subtotal), hemoglobin level, 
serum albumin level, total protein level, total choles-
terol level, triglyceride level, HDL-C level, LDL-C 
level, γ-glutamyltranspeptidase (GGT) level, aspartate 
aminotransferase (AST) level, alanine aminotransfer-
ase (ALT) level and the glycosylated hemoglobin 
(HbA1c) level. The HbA1c level was estimated as the 
National Glycohemoglobin Standardization Program 
(NGSP) equivalent value (%), which was calculated 
by the following formula: HbA1c (%)=HbA1c (Japan 
Diabetes Society: JDS) (%)＋0.4%, considering the 
relational expression of HbA1c (JDS) (%) measured by 
the previous Japanese standard substance and mea-
surement methods and the HbA1c (NGSP)9). 
Three controls were matched by preoperative age 
mellitus2). Elevated HDL-C levels, accompanied by 
low cholesterol ester transfer protein (CETP) activity, 
improve the glycemic control in patients with diabe-
tes3).
Bariatric surgery has recently become a feasible 
option for the treatment of morbid obesity, and 
increasing reports have demonstrated its beneficial 
effects on various comorbidities, including distinct 
elevations in the HDL-C level4-7). Bariatric surgery 
can dramatically resolve diabetes, often without a clear 
relationship to postoperative weight loss. The eleva-
tion in the HDL-C level following bariatric surgery 
can be partly accounted for by body weight reduction, 
but larger-than-expected increases in the HDL-C level 
may occur with lifestyle modification. 
Based on the above-described findings of previ-
ous studies, we speculated that gastrectomy itself may 
lead to elevation in the HDL-C levels. However, few 
studies have reported the long-term influence of gas-
trectomy on the HDL-C levels in the nonobese popu-
lation, because it is difficult to obtain epidemiological 
data on this topic. 
Aim
The aim of this study was to compare the pre- 
and post-gastrectomy plasma lipid changes in non-
obese patients with those of age- and sex-matched 
controls in a long-term follow-up, and to identify the 
factors that contribute to elevation of the HDL-C 
level after gastrectomy. 
Methods
Study Design and Data Source
We conducted a case-control study using annual 
health check-up data collected from 1984 to 2013 at 
Hokuriku Central Hospital, Oyabe, Toyama, Japan. 
The cases were patients who had undergone curative 
gastrectomy for the treatment of any condition that 
had newly developed during the study period. The 
controls were age- and sex-matched to the cases; they 
had not undergone gastrectomy. The exclusion criteria 
were postoperative recurrence of gastric cancer, the 
development of other malignancies during the follow-
up period, a history of gastrointestinal surgery, morbid 
obesity (body mass index [BMI] ＞30 kg/m2), current 
administration of statins or other lipid-modifying 
drugs and current medical treatment for diabetes. All 
patients were enrolled from 1984 to 2003 and were 
followed for up to 10 years. 
The Department of Health at Hokuriku Central 
Hospital provides annual health checkups for public 
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and age- and sex-matched controls are summarized in 
Table 1. The mean preoperative age of all patients was 
53.3±7.2 years, and 48 (75%) were men. The mean 
preoperative age of the controls was 53.2±6.9 years. 
There were no significant differences in the BMI, 
hemoglobin level, serum albumin level, total protein 
level, triglyceride level, HDL-C level, LDL-C level, 
GGT level, HbA1c level or daily smoking or alcohol 
consumption between the two groups. Although all 
assessed values were within their reference ranges, the 
cases had slightly lower AST, ALT and total choles-
terol levels (p＜0.05) at the time of matching. 
The mean percent changes in biochemical 
parameters for up to 10 years after baseline in both 
groups are shown in Fig.1. The mean preoperative 
BMI among the cases was 22.8±3.0 kg/m2. The BMI 
decreased maximally by one year after gastrectomy (mean 
±SD: 20.5±1.1 kg/m2, －9.6%±0.8%, p＜0.01). After 
a slight recovery, the BMI among the cases plateaued 
at approximately －8.0% from baseline (Fig.1A).
The mean serum HDL-C level among the cases 
was 54±14 mg/dL at baseline, and significantly increased 
one year after gastrectomy (64±2 mg/dL, ＋21%±
5%), further increased to approximately ＋30% at six 
years (70±2 mg/dL, ＋30%±5%), and remained at 
this level for the rest of the follow-up period (Fig.1B). 
The HDL-C levels of the cases were significantly 
higher than those of the controls throughout the fol-
low-up period (p＜0.01). 
Regarding other lipid parameters, the mean pre-
operative triglyceride level among the cases was 120±
61 mg/dL, and was significantly lower two to six years 
after gastrectomy compared to that among the con-
trols (Fig.1C). The mean preoperative LDL-C level 
among the cases was 128±33 mg/dL, and was signifi-
cantly lower one to five years and seven years after gas-
trectomy than that among the controls (Fig.1D). 
These changes in LDL-C were less distinctive than the 
changes in the HDL-C.
The mean preoperative levels of serum AST and 
ALT among the cases were 22.0±7.1 and 22.1±15.7 
IU/L, respectively, and both values were significantly 
lower than those among the controls (Table 1). The 
serum AST level, but not the serum ALT level, 
increased after gastrectomy and was consistently 
higher (although usually still within the reference 
range) than that of the controls during the follow-up 
period (data not shown). The absolute value of serum 
AST was higher in the cases than in the controls at 
some time points, although most elevations were still 
within the reference range (31.4±3.3 vs. 24.3±1.4 
IU/L, respectively; maximal difference at 10 years, p＜
0.01). The mean GGT level among the cases was 30.1 
and sex to each case. The date for each visit were 
recorded once yearly for 10 years. All blood samples 
were drawn at 9:00 am following an overnight fast. All 
assays were conducted at the laboratory of Hokuriku 
Central Hospital. The hemoglobin levels were ana-
lyzed using an autoanalyzer (Sysmex SE-9000; Sysmex 
Corporation, Kobe, Japan). The HbA1c level was mea-
sured by high-performance liquid chromatography 
(Automatic Glycohemoglobin Analyzer ADAMS A1c 
HA-8160; Arkray, Kyoto, Japan). The total cholesterol 
concentrations were determined with L-type CHO-M 
(Wako Pure Chemical Industries, Osaka, Japan), and 
the triglyceride concentrations were determined with 
Pureauto S TG-N (Sekisui Medical Co., Tokyo, 
Japan). The plasma levels of HDL-C were determined 
using Cholestest N HDL (Sekisui Medical Co.), as 
described previously. The concentration of LDL-C 
was estimated by the Friedewald equation when the 
triglyceride level was ＜400 mg/dL10). 
Statistical Analyses
Follow-up data were analyzed as the percent 
changes from the baseline year (Year 0). All variables 
were tested for normality using the Shapiro-Wilk 
method. The changes in the cases’ data were compared 
with the changes in the age- and sex-matched controls’ 
data at each follow-up year using the Student’s t-test 
for parametric variables and the Wilcoxon signed-rank 
test for nonparametric variables. The χ2 test was used 
for categorical variables. All reported p-values are two-
sided. A correlation analysis was performed using 
Spearman’s method to examine the baseline variables 
(non-normal distribution), and Pearson’s method was 
used to examine relationships between longitudinal 
changes, because the relative changes from baseline 
were normally distributed. The JMP statistical soft-
ware program version 10.0.1 for Windows (SAS Insti-
tute Inc., Cary, NC, USA) was used for all calcula-
tions, and differences were considered to be statisti-
cally significant for values of p＜0.05. Correction for 
multiple comparisons was not taken into account 
because the comparisons were descriptive in nature. 
Results
We identified 64 patients (cases) who underwent 
curative gastrectomy and had available pre- and post-
operative data during the study period. Sixty cases 
underwent subtotal gastrectomy, and four underwent 
total gastrectomy. Fifty-nine cases had early gastric 
cancer, two had gastric submucosal tumors, and three 
had duodenal ulcers. 
The baseline clinical characteristics of the cases 
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Fig.1. The mean postoperative percent changes in parameters during the 10-year follow-up period in the control and gastrectomy 
groups
Panel A: BMI, B: HDL-C, C: triglycerides, D: LDL-C, E: HbA1c, F: hemoglobin. The data are expressed as the means±standard error. Aster-
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increase slowly in both groups during the 10-year fol-
low-up, and did not significantly differ between the 
two groups throughout the study period (Fig.1E). No 
patients in this study had diabetes. Four cases (6.3%) 
and 12 controls (6.3%) exhibited significantly higher 
HbA1c levels (＞6.2%) at the end of this study than at 
baseline.
The mean preoperative hemoglobin and albumin 
levels were not significantly different between the two 
groups at baseline. The hemoglobin levels among the 
cases decreased by 5%, then by 10% biphasically dur-
ing the follow-up period, as previously described fol-
lowing gastrectomy (Fig.1F). The serum albumin 
level, which is another important nutritional parame-
ter, and the total protein level showed no significant 
differences between the two groups throughout the 
study (data not shown).
A moderate correlation was observed between the 
degree of HDL-C elevation and the degree of BMI 
reduction (r=－0.40, p＜0.01) (Fig.2). However, the 
degree of HDL-C elevation was not correlated with 
the degree of changes in the HbA1c, the AST or the 
albumin levels (data not shown). 
We also investigated whether the HDL-C eleva-
tion after gastrectomy depends on the preoperative 
HDL-C or triglyceride level. We defined a basal 
HDL-C level of ＜40 mg/dL as “low HDL-C” and a 
basal triglyceride level of ＞150 mg/dL as “high TG.” 
The clinical characteristics of these subgroups are 
±16.9 IU/L and was significantly lower at two to 
seven years after gastrectomy compared to that in the 
controls (data not shown). The changes in the GGT 
level were not as clear as those reported in obese 
patients undergoing bariatric surgery because most of 
the patients in the present study showed normal GGT 
levels at baseline. 
The mean preoperative HbA1c level among the 
cases was 5.5%±0.4%. The HbA1c level tended to 
Table 1. The baseline clinical characteristics of the study subjects











































































The data are presented as the means±standard deviation.
Fig.2. The correlations between the mean postoperative 
absolute HDL-C level and the BMI one to three years 
after gastrectomy
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one year after gastrectomy in the “low HDL-C” group 
was significantly greater than that in the “normal 
HDL-C” group, and that the degree of HDL-C eleva-
tion from baseline was consistently significant, irre-
spective of the baseline HDL-C level (Fig.3A). We 
also found that the degree of HDL-C elevation five 
and nine years after gastrectomy in the“high TG” 
group was significantly greater than that in the “nor-
shown in Tables 2 and 3. Patients with low HDL-C 
levels at baseline had significantly higher preoperative 
triglyceride levels than did the patients with normal 
HDL-C levels at baseline (Table 2). Patients with high 
triglyceride levels at baseline had significantly lower 
preoperative HDL-C levels than did patients with 
normal triglyceride levels at baseline (Table 3). 
We found that the degree of HDL-C elevation 
Table 2. The baseline characteristics of patients who underwent gastrectomy with and without a low preoperative HDL-C level
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The data are presented as the means±standard deviation.
Table 3. The baseline characteristics of patients who underwent gastrectomy with and without preoperative triglyceride elevation




Procedure (total gastrectomy/subtotal gastrectomy)
Preoperative































































The data are presented as the means±standard deviation.
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trectomy, but no statistically significant changes were 
observed in patients with a BMI of ≤ 22 kg/m2 (Fig.4A). 
The HDL-C levels were significantly higher than 
those at baseline in all patients throughout the follow-
up period, regardless of whether the BMI was ＞22 or 
≤ 22 kg/m2 (Fig.4B). 
Finally, we investigated whether the degree of 
elevation in the HDL-C level after gastrectomy was 
affected by sex. The HDL-C levels were significantly 
higher than the baseline level throughout the post-
gastrectomy follow-up period in men, and at one, 
mal TG” group, and that the degree of HDL-C eleva-
tion from baseline was consistently significant, irre-
spective of the baseline triglyceride level (Fig.3B). 
Next, we investigated whether the baseline BMI 
influences the degree of HDL-C elevation associated 
with gastrectomy. The Japan Society for the Study of 
Obesity originally defined an “ideal body weight” as a 
BMI of 22 kg/m2 11). We found that the triglyceride 
levels in patients with a BMI of ＞22 kg/m2 were sig-
nificantly lower than the baseline level throughout the 
follow-up period year, except for seven years after gas-
Fig.3. The results of the subanalyses in the gastrectomy group
A: The mean postoperative percent changes in the serum HDL-C levels during the 10-year follow-up period in the “normal HDL-C” and 
“low HDL-C” groups. B: The mean postoperative percent changes in the serum HDL-C levels during the 10-year follow-up period in the 
“normal TG” and “high TG” groups. Asterisks denote p＜0.01 and daggers denote p＜0.05 for comparisons with the baseline.
A B
Fig.4. The results of the subanalyses in the gastrectomy group
A: The mean postoperative percent changes in the serum triglyceride levels during the 10-year follow-up period in patients with a BMI ≤ 22 
or ＞22 kg/m2. B: The mean postoperative percent changes in the serum HDL-C levels during the 10-year follow-up period in patients with 
a BMI ≤ 22 or ＞22 kg/m2. Asterisks denote p＜0.01 and daggers denote p＜0.05 for comparisons with the baseline.
A B
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with the findings in age- and sex-matched controls. 
The increases in the HDL-C level showed a significant 
negative correlation with the decreases in the BMI, 
although the patients in this study were not obese and 
did not have diabetes. The HDL-C elevations were 
consistently significant, irrespective of the baseline tri-
glyceride level, baseline HDL-C level or baseline body 
weight. Our results indicate, for the first time, that 
weight reduction in association with gastrectomy may 
cause long-term HDL-C elevations, even in the non-
obese population.
Our study showed a 2.8-mg/dL HDL-C increase 
for every 1-kg decrease in body weight after gastrec-
tomy (15-mg/dL increase in HDL-C with a 5.4-kg 
body weight reduction; BMI decreased from 22.8 to 
20.8 kg/m2). Although a low HDL-C level is a com-
mon feature of metabolic syndrome, the increases in 
HDL-C levels associated with lifestyle modifications 
that promote weight reduction are reported to be rela-
three, four and six years post-gastrectomy in women. 
No significant changes were observed between men 
and women throughout the follow-up period (Fig.5).
The pre-baseline serum lipid levels were available 
for most patients, and no differences in lipid levels 
were observed between three and five years pre-base-
line and at the baseline in this study (Table 4). The 
presence of advanced cancer may decrease the HDL-C 
level before the diagnosis of the cancer. However, all 
cases in our study were cured with gastrectomy, pre-
sumably because all had undergone mandatory peri-
odic health checkups that included gastric endoscopy, 
which facilitated the early detection of gastric cancer.
Discussion
We found that gastrectomy in nonobese patients 
caused a distinct elevation in the HDL-C level, and 
that this elevation persisted for 10 years compared 
Fig.5. The results of the subanalyses in the gastrectomy group
The mean postoperative percent changes in the serum HDL-C levels during the 
10-year follow-up period in men and women. Asterisks denote p＜0.01 and 
daggers denote p＜0.05 for comparisons with the baseline.
Table 4. The lipid parameters three to five years before gastrectomy and at baseline
Three to five years before baseline
n =44



















The data are presented as the means±standard deviation.
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markedly higher HDL-C level after bariatric surgery 
than after medical therapy alone13). 
Prospective studies have shown that the serum 
total cholesterol level decreases prior to the diagnosis 
of malignant disease19-21). In the present study, there 
were no significant differences between the three- and 
five-year pre-baseline and baseline HDL-C levels, and 
no difference was seen in the HDL-C levels between 
the cases and controls. The presence of advanced can-
cer may decrease the serum HDL-C level before the 
diagnosis of the cancer; however, all cases in our study 
were cured by gastrectomy, presumably because they 
had undergone the mandatory periodic health check-
ups that included gastric fiberscopy. The effect of 
latent gastric cancer on the lipid levels therefore 
seemed to be relatively small in this study. 
A recent review of many studies found that the 
association between low baseline HDL-C levels and 
cancer risk is shared among many types of cancer, and 
is linked to obesity and inflammation22). Previous 
studies focusing on HDL-C showed that the serum 
HDL-C levels were lower in patients with than with-
out gastrointestinal cancer23-25). Tamura et al. reported 
that lymphatic invasion and vascular invasion were 
significantly more severe in patients with low HDL-C 
levels than in those with normal HDL-C levels, and 
that the serum HDL-C level may be a clinical prog-
nostic factor in patients with gastric cancer26). There 
was no significant difference in the baseline HDL-C 
levels between the cases and controls in the present 
study. All patients in our study were cured with gas-
trectomy; therefore, none of the cases had unresectable 
cancer. Additionally, their baseline serum HDL-C lev-
els were not low prior to the diagnosis of gastric can-
cer. Therefore, we speculate that latent gastric cancer 
has limited effects on the HDL-C level.
Only patients with a BMI of ＞22 kg/m2 in our 
study exhibited a decline in the triglyceride level after 
gastrectomy. However, the HDL-C levels increased 
after gastrectomy regardless of the baseline BMI. Our 
results indicate that a low adiposity level is not a deter-
minant of HDL-C elevation.
In women, menopause is associated with dyslip-
idemia, characterized by an increased very-low-density 
lipoprotein triglyceride level and a decreased HDL-C 
level27). In the present study, the HDL-C level 
increased after gastrectomy regardless of sex. All 
women in this study were postmenopausal with the 
exception of one who was 44 years old at baseline. 
Therefore, menopause also seemed to have a small 
impact in this study.
Craig et al. showed that smokers had significantly 
lower serum concentrations of HDL-C (－5.7%) than 
tively small. The results of a meta-analysis of 70 stud-
ies showed that the BMI decreased from 34.8 to 27.8 
kg/m2 with dietary management; and there was a 
0.35-mg/dL HDL-C increase for every 1-kg decrease 
in body weight in that study12). The rate of increase in 
the HDL-C level was almost 10 times higher in the 
present study than in that study. In another study, a 
marked increase in the HDL-C level occurred 12 
months after gastric bypass and sleeve gastrectomy 
(28.5% and 28.4%, respectively) in association with 
body weight reduction (－29.4 and －25.1 kg, respec-
tively)13).
The amelioration of insulin resistance does not 
adequately explain the HDL-C elevation in this study. 
The HbA1c level in the two groups remained substan-
tially unchanged during the follow-up period despite 
the decreased hemoglobin levels in the gastrectomy 
group. One reason for this finding is that patients 
with diabetes were not included in this study. The 
presence of anemia after gastrectomy may affect the 
HbA1c level, and the hemoglobin level was signifi-
cantly lower in the patients who underwent gastrec-
tomy at all follow-up points. The anemia could have 
concealed the exacerbation of preexisting diabetes, but 
this cannot explain the HDL-C elevation in this study. 
We showed that neither a low baseline HDL-C 
level nor a high baseline triglyceride level is a determi-
nant of the HDL-C elevation after gastrectomy. Laws 
and Reaven showed that a high triglyceride level and 
low HDL-C level are strong indicators of insulin resis-
tance14), and are frequently correlated with each other. 
Insulin resistance may not a relevant feature in the 
present population, because most post-gastrectomy 
patients in this study had triglyceride levels, HbA1c 
levels and BMIs within the reference ranges. The base-
line HDL-C and triglyceride levels are reportedly 
highly predictive of the increase in HDL-C induced 
by statins15). However, in the present study, the base-
line HDL-C and triglyceride levels were not predictive 
of the increase in the HDL-C level after gastrectomy. 
It is considered that gastrectomy is a major factor 
leading to the HDL-C elevation, because it was the 
main intervention in this study. Reports of the effects 
of bariatric surgery on morbid obesity can provide 
important information with regard to this finding. 
Weight loss following bariatric surgery always pro-
duces substantial decreases in the fasting triglyceride 
levels, and an increase in the HDL-C level has been 
seen in most studies. Observational studies have 
reported 40-63% decreases in the serum triglyceride 
level, 20-39% increases in the HDL-C level and 
19-31% decreases in the LDL-C level after Roux-en-Y 
gastric bypass16-18). Schauer et al. recently reported a 
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nonobese patients, and this may lead to the increase in 
HDL-C.
Unexpectedly, a slight but statistically significant 
elevation in the AST level occurred after gastrectomy 
in this study. One explanation for this finding is inef-
fective hematopoiesis after gastrectomy. This may 
explain the lack of an association between the changes 
in the AST and ALT levels (ALT is more specific to 
hepatocytes).
Conclusion
In this long-term study, gastrectomy was associ-
ated with a distinct elevation in the HDL-C level with 
BMI reduction, even in nonobese patients. Resolution 
of insulin resistance is not likely to be the main cause 
of the HDL-C level elevation in such patients. The 
HDL-C level elevation was consistently significant 
irrespective of the baseline triglyceride level, baseline 
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one control, but no cases quit drinking. Therefore, 
smoking and alcohol consumption seemed to have 
only a limited effect on the HDL-C levels in this 
study. 
Exercise training increases the serum HDL-C 
level by 5-10% while lowering the CETP level30, 31). 
Inflammation also affects the HDL-C level, and a 
reduced HDL-C level is correlated with an elevated 
serum CRP level. Thus, elevated inflammatory activ-
ity due to conditions such as cancer and metabolic 
syndrome22, 32) may lead to reduced HDL-C and 
increased serum CRP levels. The patients’ exercise his-
tories and serum CRP levels were not available in the 
present study, which represents a limitation of this 
work.
HDL metabolism is complex, and is regulated by 
many factors. Lipoprotein lipase, hepatic lipase, endo-
thelial lipase, lecithin cholesterol acyltransferase, and 
CETP all modify HDL metabolism33). Some studies 
have shown that the fasting lipoprotein lipase activity 
is increased in the abdominal and gluteal subcutane-
ous adipose tissue after weight loss34, 35). CETP is a 
plasma glycoprotein that facilitates the transfer of cho-
lesteryl esters from HDL-C to apolipoprotein B-con-
taining lipoproteins36). Inhibition of CETP is a pro-
posed strategy to raise the HDL-C levels37). In obese 
rats lacking CETP, sleeve gastrectomy did not increase 
the plasma HDL-C levels compared to those of con-
trol rats38). Doğan et al. reported that the increase in 
the level of large HDL particles after laparoscopic 
sleeve gastrectomy in obese patients was accompanied 
by a decrease in the CETP level39). Asztalos et al. 
reported that CETP activity continually decreased 
throughout a 12-month follow-up period, and that 
the HDL-C level increased after Roux-en-Y gastric 
bypass surgery in obese patients40). Alcohol-induced 
HDL-C elevation is a well-known condition that is 
reportedly accompanied by lower CETP activity41, 42). 
The present study showed no significant differences in 
the level of alcohol consumption at baseline or during 
the follow-up between the two groups. It is possible 
that the body weight reduction after gastrectomy can 
decrease both the CETP expression and activity in 
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